Videos

In his brand new video series, Frank A. Clark, MD, sits down with an expert to discuss parental leave and how it relates to psychiatry.

"Doctors in their lonely rounds, Poets with their sacred sounds, Human kindness that abounds shout, nothing stops the spring."

How does John Kane, MD, address issues of cognition in schizophrenia?

How can psychiatry avoid foolishness and be more like Shakespeare's fools?

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.

"Was this what Rome felt like toward the end? When the colosseums filled with gladiators stirred the masses into a frenzy."

Get ready for our new video series, "Psyched Perspectives"!

After 40 years, Psychiatric Times is still your go-to resource for all things psychiatry. Just ask our Mood Disorders Section Editor.

How can we prevent the transmission of intergenerational trauma, which persists?

While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.

Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

Our Mood Disorders Section Editor shares his thoughts on this year's biggest clinical trial successes and failures.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.

Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.

What are the most pressing issues facing psychiatry? Gustavo Alva, MD, FAPA, shares his thoughts.

"Any decent realtor, walking you through a real shithole, chirps on about good bones: This place could be beautiful, right? You could make this place beautiful."

Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Let's process our trauma, grief, and healing from COVID-19.

"I stood by her side, stunned when her breathing stopped..."

Rejoyn, a new app being prescribed as a depression treatment, is an emotional face memory task designed to correct abnormal neural circuits.

Spring is full of religious holidays, each with potential psychosocial meaning...

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.